<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977375</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2019-13-Patil-NeoPD1SRS</org_study_id>
    <nct_id>NCT04977375</nct_id>
  </id_info>
  <brief_title>Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma</brief_title>
  <official_title>Phase Ib/II Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chirag G. Patil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety/tolerability/feasibility of pembrolizumab&#xD;
      and radiation therapy before surgical resection in patients with recurrent glioblastoma as&#xD;
      defined by treatment-related AEs and the number of patients who do not necessitate a delay in&#xD;
      surgical resection, and to assess overall survival. The secondary objectives are to assess&#xD;
      progression free survival, and to assess the T cell clonality, CD8 T cell activation and&#xD;
      Tumor Infiltrating Lymphocyte (TIL) score after treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability measured by the incidence of adverse events, serious adverse events and grade 3 or above treatment related adverse events.</measure>
    <time_frame>From start of study treatment until confirmation of disease progression, intolerable toxicities, withdrawal of consent. Assessed up to 2 years.</time_frame>
    <description>Safety and tolerability measured by the incidence of adverse events, serious adverse events and grade 3 or above treatment related adverse events as assessed per CTCAE, Version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From start of study treatment until death, loss to follow-up, or withdrawal of consent. Assessed up to 2 years.</time_frame>
    <description>From start of study treatment until death, loss to follow-up, or withdrawal of consent. Subjects who are lost to survival follow-up will not be replaced, and public records may be accessed to assess Overall Survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From start of study treatment until until confirmation of disease progression, intolerable toxicities, withdrawal of consent. Assessed up to 2 years.</time_frame>
    <description>From start of study treatment until confirmation of disease progression (per iRANO Criteria), intolerable toxicities, withdrawal of consent, or up to 2 years or 18 cycles of pembrolizumab, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune action</measure>
    <time_frame>At baseline, prior to stereotactic radiation therapy, and prior to surgery.</time_frame>
    <description>To assess the T cell clonality, CD8 T cell activation and Tumor Infiltrating Lymphocyte (TIL) score after treatment. Blood draws for research purposes performed after obtaining consent but prior to neoadjuvant pembrolizumab administration, and at the time of initiation of SRT and at the time of surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab with stereotactic radiation therapy and surgical resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks</description>
    <arm_group_label>Pembrolizumab with stereotactic radiation therapy and surgical resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiation Therapy</intervention_name>
    <description>Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7</description>
    <arm_group_label>Pembrolizumab with stereotactic radiation therapy and surgical resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Resection</intervention_name>
    <description>Standard of care surgical resection of tumor on Day 10-28</description>
    <arm_group_label>Pembrolizumab with stereotactic radiation therapy and surgical resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Confirmed histologic diagnosis of WHO Grade IV, Glioblastoma Multiforme&#xD;
&#xD;
          -  GBM recurrence or progression with planned standard of care surgical resection and&#xD;
             repeat radiation&#xD;
&#xD;
          -  Tumor size less than 6 cm&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
          -  Adequate laboratory values&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to additional radiation&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent&#xD;
             directed to another stimulatory or co-inhibitory T-cell receptor&#xD;
&#xD;
          -  Immunodeficiency diagnosis or receiving chronic systemic steroid therapy (exceeding 10&#xD;
             mg daily of prednisone) or any other form of immunosuppressive therapy&#xD;
&#xD;
          -  Severe hypersensitivity to pembrolizumab&#xD;
&#xD;
        Complete inclusion/exclusion criteria are detailed in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chirag G Patil, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Kearns</last_name>
    <phone>3109670692</phone>
    <email>Karen.Kearns@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Karen Kearns</last_name>
      <phone>310-967-0692</phone>
      <email>Karen.Kearns@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Shiao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jethro Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Rudnick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Black, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ray Chu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Mamelak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amin Mirhadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Behrooz Hakimian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Chirag G. Patil</investigator_full_name>
    <investigator_title>Associate Professor of Neurosurgery Program Director, Neurosurgery Residency Training</investigator_title>
  </responsible_party>
  <keyword>Central Nervous System Tumor</keyword>
  <keyword>neurosurgery</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>spinal cord tumor</keyword>
  <keyword>surgical resection</keyword>
  <keyword>glioma</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>neuropathology</keyword>
  <keyword>maximal safe resection</keyword>
  <keyword>CNS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

